- Home
- IQV vs EQR Comparison
IQV vs EQR Comparison
Compare IQV & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQV
- EQR
- Stock Information
- Founded
- IQV 1982
- EQR 1993
- Country
- IQV United States
- EQR United States
- Employees
- IQV N/A
- EQR N/A
- Industry
- IQV Biotechnology: Commercial Physical & Biological Resarch
- EQR Real Estate Investment Trusts
- Sector
- IQV Health Care
- EQR Real Estate
- Exchange
- IQV Nasdaq
- EQR Nasdaq
- Market Cap
- IQV 31.0B
- EQR 24.9B
- IPO Year
- IQV 2013
- EQR 1993
- Fundamental
- Price
- IQV $190.28
- EQR $66.12
- Analyst Decision
- IQV Strong Buy
- EQR Buy
- Analyst Count
- IQV 19
- EQR 14
- Target Price
- IQV $229.37
- EQR $76.89
- AVG Volume (30 Days)
- IQV 1.2M
- EQR 2.3M
- Earning Date
- IQV 07-22-2025
- EQR 10-29-2025
- Dividend Yield
- IQV N/A
- EQR 4.20%
- EPS Growth
- IQV N/A
- EQR 5.58
- EPS
- IQV 6.92
- EQR 2.65
- Revenue
- IQV $15,700,000,000.00
- EQR $3,044,764,000.00
- Revenue This Year
- IQV $6.01
- EQR $5.10
- Revenue Next Year
- IQV $5.05
- EQR $4.21
- P/E Ratio
- IQV $27.56
- EQR $24.86
- Revenue Growth
- IQV 3.60
- EQR 4.40
- 52 Week Low
- IQV $134.65
- EQR $59.41
- 52 Week High
- IQV $252.88
- EQR $78.84
- Technical
- Relative Strength Index (RSI)
- IQV 56.25
- EQR 57.28
- Support Level
- IQV $185.38
- EQR $64.33
- Resistance Level
- IQV $193.23
- EQR $65.70
- Average True Range (ATR)
- IQV 4.03
- EQR 0.97
- MACD
- IQV -0.87
- EQR 0.36
- Stochastic Oscillator
- IQV 56.89
- EQR 98.05
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.